Roche Diagnostics Australia   ›   Roche's response to the COVID-19 pandemic

Roche’s response to the COVID-19 pandemic

Coronavirus close up

COVID-19 pandemic

 

Timely availability and fast access to reliable, high quality tests are essential for healthcare systems.

Thomas Schinecker
Chief Executive Officer of Roche Diagnostics

Our commitment to help put a stop to the COVID-19 pandemic

 

Roche is deeply committed to supporting the global response to put an end to the COVID-19 pandemic.

Around the world, we are working with urgency, passion and purpose each and every day to deliver high-quality tests that are essential for healthcare systems and patients alike.

COVID-19

Roche policy positions on COVID-19 Testing in Australia

 
Rapid antigen tests are a key testing technology currently underutilised in Australia, which can play a fundamental role in supporting Australia’s National COVID Response.
 
This document has largely focussed on the use of rapid antigen tests given their importance, particularly with the emergence of more rapidly transmissible variants of SARS-CoV-2 (the virus).
Download the white paper

 

COVID-19 Rapid Antigen Testing and Tracking Solutions

 

Roche solutions offer a fast and effective way to help protect businesses from COVID-19, enabling further confidence in a COVID-19 Safety Plan.

 

Learn More 

Rapid Antigen Test

The SARS-CoV-2 Rapid Antigen Test must not be supplied for the purpose of self-testing

The SARS-CoV-2 Rapid Antigen Test must only be used by relevant practitioners, or persons under their supervision, who are trained in the correct use of the goods and the interpretation of the test results

Negative test results do not exclude infection with COVID-19 (so face masks, social distancing and good hygiene practice must be maintained)

Positive test results or a symptomatic persons require immediate confirmatory testing with a polymerase chain reaction (PCR) test

 

Supporting our Customers through the pandemic

 

Roche analysers have assisted our customers in fast-tracking test results for COVID-19 samples, taking pressure off pathology staff. Roche Diagnostics Australia is continually committed to providing our customers with solutions to manage the pandemic response.

Detecting SARS-CoV-2 in currently infected patients with high sensitivity

PoC tests icon

Point of Care tests

Molecular test (PCR)

 

The cobas® SARS-CoV-2 & Influenza A/B Assay is an automated multiplex real-time RT-PCR assay intended for the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2., influenza A, and influenza B in nasopharyngeal and nasal swabs from patients suspected of respiratory viral infection.

The test is run on Roche's molecular point-of-care PCR testing solution, the cobas® Liat® System, and has been included on the ARTG.

All trademarks used or mentioned are protected by law.

Rapid Antigen Test

 

The SARS-CoV-2 Rapid Antigen Test is a reliable, rapid chromatographic immunoassay for the qualitative detection of specific antigens of SARS-CoV-2 present in the human nasopharynx.

Rapid Antigen Test Nasal

 

The SARS-CoV-2 Rapid Antigen Test Nasal is a reliable, rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen present in human nasal samples.

Our rapid testing solutions not only add a layer of confidence to your employees but can act as part of a risk mitigation strategy to protect your business continuity and help keep your business running. 

  • The SARS-CoV-2 Rapid Antigen Test must not be supplied for the purpose of self-testing
  • The SARS-CoV-2 Rapid Antigen Test must only be used by relevant practitioners, or persons under their supervision, who are trained in the correct use of the goods and the interpretation of the test results
  • Negative test results do not exclude infection with COVID-19 (so face masks, social distancing and good hygiene practice must be maintained)
  • Positive test results or a symptomatic persons require immediate confirmatory testing with a polymerase chain reaction (PCR) test
Instrument Icon

Laboratory tests

Molecular test (PCR)

 

The cobas® SARS-CoV-2 Test is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from patients.

The cobas® SARS-CoV-2 & Influenza A/B Test is a real-time RT-PCR test intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in nasal or nasopharyngeal swab samples collected from patients. 

Both tests have been included on the Australian Register of Therapeutic Goods (ARTG) and can run on Roche's fully automated cobas® 6800 and cobas® 8800 Systems. 

Elecsys® SARS-CoV-2 Antigen

 

The Elecsys® SARS-CoV-2 Antigen is an immunoassay for the qualitative detection of the SARS-CoV-2 nucleocapsid antigens.

If you would like further information concerning the products listed, please contact your local Roche Diagnostics Australia representative.

All trademarks used or mentioned are protected by law.

 

Get in touch to find out more about our COVID-19 solutions

Form Successfully Submitted!
Thank you for your submission!
text